Serge Belanger
Stock Analyst at Needham
(4.62)
# 207
Out of 5,141 analysts
388
Total ratings
55.77%
Success rate
24.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Serge Belanger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix | Maintains: Buy | $20 → $18 | $7.78 | +131.36% | 7 | Feb 20, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $46 → $48 | $35.58 | +34.91% | 11 | Feb 18, 2026 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $42 | $27.44 | +53.06% | 20 | Feb 4, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $31 | $25.42 | +21.98% | 24 | Jan 26, 2026 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $32 → $35 | $15.83 | +121.10% | 24 | Jan 9, 2026 | |
| PCRX Pacira BioSciences | Maintains: Buy | $30 | $23.22 | +29.20% | 29 | Jan 9, 2026 | |
| CRMD CorMedix | Maintains: Buy | $16 → $15 | $7.03 | +113.37% | 20 | Jan 8, 2026 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $48 → $56 | $45.00 | +24.44% | 27 | Jan 8, 2026 | |
| EOLS Evolus | Reiterates: Hold | n/a | $4.37 | - | 17 | Dec 24, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $72 → $84 | $67.94 | +23.64% | 26 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $29.17 | +23.41% | 2 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $28.53 | +19.17% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $7.45 | +141.61% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $52 | $33.59 | +54.81% | 34 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $55 | $42.23 | +30.24% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $12.04 | - | 9 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $20 | $18.77 | +6.55% | 14 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.18 | +154.24% | 23 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $22 | $10.64 | +106.77% | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $5.79 | - | 19 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $3.48 | +14.94% | 20 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.18 | - | 1 | Mar 31, 2022 |
Ocular Therapeutix
Feb 20, 2026
Maintains: Buy
Price Target: $20 → $18
Current: $7.78
Upside: +131.36%
NewAmsterdam Pharma Company
Feb 18, 2026
Maintains: Buy
Price Target: $46 → $48
Current: $35.58
Upside: +34.91%
Viridian Therapeutics
Feb 4, 2026
Reiterates: Buy
Price Target: $42
Current: $27.44
Upside: +53.06%
Arcutis Biotherapeutics
Jan 26, 2026
Maintains: Buy
Price Target: $30 → $31
Current: $25.42
Upside: +21.98%
KalVista Pharmaceuticals
Jan 9, 2026
Maintains: Buy
Price Target: $32 → $35
Current: $15.83
Upside: +121.10%
Pacira BioSciences
Jan 9, 2026
Maintains: Buy
Price Target: $30
Current: $23.22
Upside: +29.20%
CorMedix
Jan 8, 2026
Maintains: Buy
Price Target: $16 → $15
Current: $7.03
Upside: +113.37%
Collegium Pharmaceutical
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $56
Current: $45.00
Upside: +24.44%
Evolus
Dec 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $4.37
Upside: -
Cytokinetics
Dec 22, 2025
Maintains: Buy
Price Target: $72 → $84
Current: $67.94
Upside: +23.64%
Nov 11, 2025
Reiterates: Buy
Price Target: $36
Current: $29.17
Upside: +23.41%
Nov 7, 2025
Maintains: Buy
Price Target: $36 → $34
Current: $28.53
Upside: +19.17%
Nov 4, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $7.45
Upside: +141.61%
Nov 4, 2025
Maintains: Buy
Price Target: $36 → $52
Current: $33.59
Upside: +54.81%
Nov 4, 2025
Reiterates: Buy
Price Target: $55
Current: $42.23
Upside: +30.24%
Oct 15, 2025
Reiterates: Hold
Price Target: n/a
Current: $12.04
Upside: -
Sep 30, 2025
Maintains: Buy
Price Target: $66 → $20
Current: $18.77
Upside: +6.55%
Aug 8, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.18
Upside: +154.24%
Aug 8, 2025
Maintains: Buy
Price Target: $24 → $22
Current: $10.64
Upside: +106.77%
May 14, 2025
Reiterates: Hold
Price Target: n/a
Current: $5.79
Upside: -
May 7, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $3.48
Upside: +14.94%
Mar 31, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.18
Upside: -